Intellectual Property, Grau & Angulo updates


Contributed by Grau & Angulo
Preliminary injunction request dismissed due to prima facie invalidity of asserted SPC
  • Spain
  • 15 October 2018

Barcelona Commercial Court Number 5 recently dismissed a preliminary injunction request filed by Merck Sharp & Dohme (MSD) regarding the commercialisation of generic medicinal products. The defendants had opposed the request by alleging the invalidity of MSD's supplementary protection certificate (SPC) on the basis that it was invalid according to the EU SPC for Medicinal Products Regulation.

Criminal sentence for importers of counterfeit t-shirts
  • Spain
  • 30 July 2018

The Zaragoza Court of Appeal recently issued a ruling confirming a trial court judgment which had sentenced two defendants for importing several thousand counterfeit t-shirts from China. In their appeal against the trial court's condemnatory judgment, the defendants had argued that the trial court erred in assessing the evidence, that there had been a break in the custody chain of the seized goods, that one of the defendants had not participated in the importation and that there had been no consumer error.

Appeal court stresses importance of drawings for defining a patent's scope of protection
  • Spain
  • 23 July 2018

The Madrid Court of Appeal (Section 28) recently confirmed the dismissal of a patent infringement action filed by PERI GmbH against Spanish company Sistemas Técnicos de Encofrados (STEN). The court held that a patent's scope of protection is determined by its claims and that the patent description and drawings must be considered in an interpretation of the claims. In light of this, the court concluded that STEN's scaffolding did not infringe PERI's patent.

Barcelona patent court upholds valsartan-amlodipine patent invalidity
  • Spain
  • 18 June 2018

The Barcelona Commercial Court Number 4 recently dismissed a patent infringement action brought by Novartis against the first generics in Spain of its valsartan and amlodipine medicinal product for the treatment of hypertension. The court upheld the defendants' counterclaim for invalidity of the asserted patent. Novartis has appealed this decision before the Barcelona Court of Appeal.

Appeal court confirms revocation of ex parte preliminary injunctions against oxycodone/naloxone generics
  • Spain
  • 11 June 2018

The Barcelona Court of Appeal recently issued two decisions confirming the Barcelona Commercial Court Numbers 1 and 4 rulings revoking the preliminary injunctions that they had granted ex parte at Mundipharma's request against the first generics in Spain of its oxycodone/naloxone medicinal product for the treatment of pain. In its decisions, the Barcelona Court of Appeal concluded that Mundipharma's patent was prima facie invalid due to added subject matter, as argued by the defendants.

Current search